

Special Issue

Hepatitis B Virus Research in Italy: From Epidemiology to Treatment

Message from the Guest Editor

More than fifty years since the discovery of the Australian antigen, hepatitis B virus (HBV) infection still represents a continuous challenge. Vaccination against HBV has represented a milestone for the control of this devastating disease, and there is optimism for new effective drugs for the treatment of hepatitis B. This Special Issue titled “Hepatitis B virus research in Italy: from epidemiology to treatment” will include a range of invited articles from Italian researchers. Italy was the first country to adopt a peculiar model of HB vaccination policy, which has nearly eliminated the acute infection. Moreover, important insights have been provided from Italian researchers on the epidemiology, prevention, natural history, diagnostics, and treatment of HBV infection. Articles in this Issue will deal with these topics with the collaboration of Italian researchers who have greatly improved the worldwide knowledge regarding HBV infection. Finally, an article will deal with major negative side effect of the existence of HBsAg(i.e. HDV), first discovered in Italy in the second half of the 1970s by Rizzetto et al.

Guest Editor

Dr. Tommaso Stroffolini
Azienda Policlinico Umberto, Rome, Italy

Deadline for manuscript submissions

closed (30 June 2022)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/104044

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/

[viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).